v3.26.1
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development expenses $ 679 $ 4,716
General and administrative expenses 1,279 336
Total operating expenses 1,958 5,052
Operating loss (1,958) (5,052)
Other expense – direct listing offering costs (586)
Net loss and comprehensive loss $ (2,544) $ (5,052)
Net loss per share – basic $ (0.05) $ (0.11)
Net loss per share – diluted $ (0.05) $ (0.11)
Weighted average common shares outstanding – basic 47,219,329 44,338,960
Weighted average common shares outstanding – diluted 47,219,329 44,338,960